The COVID-19 pandemic should be last orders for poor care of people with neurodevelopmental disorders

Andre Strydom, Elizabeth Corcoran and Anne-Sophie Rebillat

Summary

We explore whether the needs of individuals with neurodevelopmental disorders have been overlooked during the coronavirus disease 2019 (COVID-19) pandemic and set out the issues that need to be considered in response to future health crises and pandemics.

Keywords

COVID; neurodevelopmental disorders; carers; intellectual disability; autism spectrum disorders.

Gaps in understanding of risks, presentation of disease and outcomes

During the initial stages NDD communities grappled with the question ‘am I/they vulnerable?’, ‘should I shield?’ based solely on their diagnosis of NDD. Given the gaps in basic immunology and physiological research into their conditions, combined with the absence of widespread testing, clinicians and community leaders could not provide them with evidence-based advice about extra protection or shielding. Survey data has, however, provided a valuable snapshot of NDD communities highlighting that rates of multimorbidity and poly-pharmacy are still predominant, suggesting an increased risk for more severe COVID-19 (https://www.dsrf-uk.org/covid19results2/).

During the course of the pandemic the high risk to individuals with NDDs have become increasingly apparent. For example, people with Down syndrome were shown to have three times the mortality risk after developing COVID-19 symptoms, and at a much younger age, than their peers in the general population. These were associated with their increased rates of comorbidities such as Alzheimer’s disease and obesity as well as innate immune system dysfunction. Other individuals with NDD particularly those with intellectual disabilities, also appear to be at increased risk for both admission to hospital and mortality because of COVID-19. It is not yet clear to what extent this increased risk is explained by environmental factors such as living in care settings and difficulty following safety measures such as hand-washing or using face masks, constitutional factors such as comorbidities and immune system issues, or because of individuals with NDD being disadvantaged at service-delivery level, for example, not having equal access to interventions such as ventilation.

A particular concern in the UK was the proposal to use the clinical frailty scale as a decision tool to prioritise care, without consideration of how it might be applied to individuals with NDD. With a focus on functional abilities and lack of adjustment for quality of life, application of this scale in its original form would have meant that individuals with stable cognitive impairments may not have been deemed a priority for intervention, causing distress in the intellectual disability community and fuelling fears of utilitarian priorities in healthcare. Fortunately, a robust response from the NDD community resulted in the deeply flawed approach being adapted.

Background

The chaotic initial stages of the SARS-CoV-2 pandemic, which threatened to overwhelm health services in many regions in the northern hemisphere in the spring of 2020, exposed an unfortunat:le: the most vulnerable individuals, including those with neurodevelopmental disorders (NDD), remain at the margins of society and their risks, health and mental health needs during emerging pandemics are consequently overlooked. Many clinicians, patients and caregivers were surprised that a so-called herd immunity approach could be considered by politicians (and some scientists) without giving consideration to which individuals with NDDs have become increasingly apparent. For example, people with Down syndrome became three times the mortality risk after developing COVID-19 symptoms, and at a much younger age, than their peers in the general population. These were associated with their increased rates of comorbidities such as Alzheimer’s disease and obesity as well as innate immune system dysfunction. Other individuals with NDD particularly those with intellectual disabilities, also appear to be at increased risk for both admission to hospital and mortality because of COVID-19. It is not yet clear to what extent this increased risk is explained by environmental factors such as living in care settings and difficulty following safety measures such as hand-washing or using face masks, constitutional factors such as comorbidities and immune system issues, or because of individuals with NDD being disadvantaged at service-delivery level, for example, not having equal access to interventions such as ventilation.

A particular concern in the UK was the proposal to use the clinical frailty scale as a decision tool to prioritise care, without consideration of how it might be applied to individuals with NDD. With a focus on functional abilities and lack of adjustment for quality of life, application of this scale in its original form would have meant that individuals with stable cognitive impairments may not have been deemed a priority for intervention, causing distress in the intellectual disability community and fuelling fears of utilitarian priorities in healthcare. Fortunately, a robust response from the NDD community resulted in the deeply flawed approach being adapted.
The fragmentation of the care sector (and Government agencies that have responsibility for overseeing it) in many countries including the UK and the USA further complicated efforts to coordinate the response to protect people with NDD. Responsibility to provide personal protective equipment (PPE) and to keep track of cases in settings such as smaller care homes typically provided by the private sector was not clear. In some cases, this had disastrous consequences, most infamously in Spain where there were reports of people in care homes being left abandoned (https://www.bbc.co.uk/news/world-europe-52014023). In contrast to the piecemeal approach to public health in the UK following the transfer of public health services from the National Health Service to local authorities in 2012, Germany has maintained a public health institute, which arguably helped it to achieve a more coherent response.3

Impact on quality of life

There have also been examples of exceptional care, with caregivers going above and beyond what is expected to support people with NDD; for example, moving in with the vulnerable person during the lockdown so as to limit exposure through employing multiple caregivers. Some large care organisations in the USA mobilised early, and developed systems to monitor outbreaks in individual homes and implemented a rapid response.4 Others eventually implemented regular testing for care workers to limit exposure to residents, and most care homes followed strict social distancing guidelines. This successfully limited the infection rate in many facilities. However, it came at a cost – many people with NDD, who benefit from the structure and predictability of a regular routine, found the change in their daily routines challenging, and others had to forego face-to-face contact with families and friends. Given that people with NDD and their families often have limited social networks, the requirement for social distancing may have resulted in significant social isolation. Furthermore, organised social, educational and occupational activities are often an essential part of care plans to maintain mental and physical health and keep people active. The loss of these activities during the lockdown may have resulted in increased functional impairment, as well as an increase in mental health and behavioural issues. Whether this will affect longer-term mental and physical health outcomes remains unknown.

Planning for the future

For all of these reasons, it is of utmost importance to include a comprehensive consideration of the needs of individuals with NDD in planning our response to future health crises and pandemics such as COVID-19. We suggest an urgent focus on improving and coordinating response to protect people with NDD, particularly those with additional risk factors, should be prioritised for treatment and interventions, including immunisation with the coronavirus vaccine. In order to facilitate this, people with NDD should be included in vaccine trials, as there may be a different antibody response in some groups. In addition to the flu vaccine, individuals such as those with Down syndrome who have an increased rate of death because of pneumonia may also benefit from pneumococcal vaccination. Many people with NDDs are deficient in Vitamin D, particularly during winter months, and supplementation may be beneficial during pandemics involving respiratory pathogens given some evidence that it may modulate host responses to respiratory infections.5

Last but not least, it is important to consider the mental health impact of pandemics, including the potential impact of lockdowns and shielding. Loss of structured activities should be replaced with alternatives during lockdowns, and individuals with NDD should be monitored for signs of mental health concerns. There are concerns that the fall-out from the current pandemic may include loss of funding for facilities and supports on which individuals with NDD and their caregivers depend to maintain their mental health and quality of life; clinicians working with individuals with NDD will need to strongly advocate for their continued access to such support. From a human rights perspective, public health policies should benefit vulnerable people too, and not solely focus on maintaining the economy. However, the decisions taken today in terms of public health should not only be based on the conditions of the first wave, but also take into account the progress made in medical care with reduction in mortality rates, and the capacity of people with NDD to respect health rules.

Conclusions

There have been many lessons learned during the initial stages of the COVID-19 pandemic – most importantly, that without a focus on
vulnerable people we cannot fully estimate the impact of disease at population level.

Andre Strydom, King’s College London, UK; and South London and the Maudsley Foundation NHS Trust, UK; Elizabeth Corcoran, Down’s Syndrome Research Foundation, UK; Anne-Sophie Rebillat, Jérôme Lejeune Institute, France

Correspondence: Andre Strydom. Email: andre.strydom@kcl.ac.uk

First received 9 Nov 2020, final revision 14 Dec 2020, accepted 01 Feb 2021

Author contribution
A.S., E.C. and A.S.R. co-wrote this editorial.

Declaration of interest
A.S. is president of the Trisomy 21 Research Society; E.C. runs the Down’s Syndrome Research Foundation.

References

1 Huels A, Costa ACS, Dienssen M, Baksh RA, Bargagna S, Baumer NT, et al. An international survey on the impact of COVID-19 in individuals with Down syndrome. medRxiv [Preprint] 2020. Available from: https://doi.org/10.1101/2020.11.03.20225359.

2 NHS England. COVID-19 Deaths of Patients with a Learning Disability Notified to LeDeR. NHS England, 2020 (https://www.england.nhs.uk/publication/covid-19-deaths-of-patients-with-a-learning-disability-notified-to-leder/).

3 Our World in Data. Emerging COVID-19 Success Story: Germany’s Strong Enabling Environment. Our World in Data, 2020 (https://ourworldindata.org/covid-exemplar-germany).

4 Mills WR, Sender S, Lichtefeld J, Romano N, Reynolds K, Price M, et al. Supporting individuals with intellectual and developmental disability during the first 100 days of the COVID-19 outbreak in the USA. J Intell Disab Res 2020; 64: 489–96.

5 Martineau AR, Forouhi NG. Vitamin D for COVID-19: a case to answer? Lancet Diabetes Endocrinol 2020; 8: 735–6.